| Yuan Yang,Baohua Lu,Baolan Li,Weiying Li,Mei Jiang,Wentao Yue,Qunhui Wang,Tongmei Zhang. The expression of vascular endothelial growth factor (VEGF)/ endostatin (ES) and VEGF receptor 2 (VEGFR2)/ES is associated with NSCLC prognosis. Oncol Transl Med, 2021, 7: 149-154. |
| 非小细胞肺癌术后肿瘤组织VEGF/ES 和VEGFR2/ES表达与预后相关 |
| The expression of vascular endothelial growth factor (VEGF)/ endostatin (ES) and VEGF receptor 2 (VEGFR2)/ES is associated with NSCLC prognosis |
| Received:February 25, 2020 Revised:August 10, 2021 |
| DOI：10.1007/s10330-020-0407-7 |
| 中文关键词: 非小细胞肺癌; 血管生成; 临床特征; 预后 |
| 英文关键词: non-small cell lung cancer (NSCLC); angiogenesis; clinical characteristics; prognosis |
| 基金项目: |
| Author Name | Affiliation | E-mail | | Yuan Yang* | General Department of Medicine, Beijing Chest Hospital, Capital Medical University | yangyuan1919@163.com | | Baohua Lu | General Department of Medicine, Beijing Chest Hospital, Capital Medical University | | | Baolan Li | General Department of Medicine, Beijing Chest Hospital, Capital Medical University | | | Weiying Li | Laboratory of Cell Biotechnology, Beijing Tuberculosis and Thoracic Tumor Research Institute | | | Mei Jiang | Laboratory of Cell Biotechnology, Beijing Tuberculosis and Thoracic Tumor Research Institute | | | Wentao Yue | Laboratory of Cell Biotechnology, Beijing Tuberculosis and Thoracic Tumor Research Institute | | | Qunhui Wang | General Department of Medicine, Beijing Chest Hospital, Capital Medical University | | | Tongmei Zhang | General Department of Medicine, Beijing Chest Hospital, Capital Medical University | |
|
| Hits: 5772 |
| Download times: 6857 |
| 中文摘要: |
| 目的 本研究旨在检测非小细胞肺癌（NSCLC）患者术后肿瘤组织中血管生成抑制蛋白和血管生成促进蛋白的表达，并探讨其表达与临床特征以及预后的关系。
方法 回顾性在255例术后非小细胞肺癌患者肿瘤组织中用免疫组化的方法检测VEGF, VEGFR2, ES蛋白的表达情况。评估三种蛋白的表达与临床特征如分期、组织学类型、分化程度、性别、吸烟和年龄的关系。根据VEGF/ES的数值，我们将队列分为促血管生成组A、抑制血管生成组A和平衡组A，通过评估三组之间的生存差异以检验VEGF/ES的预后参考价值。同样的方法也用来测试VEGFR2/ES的预后参考价值。
结果 VEGF阳性表达93例（36.4%）。VEGF的表达与临床特征无相关性。VEGFR2阳性表达103例（40.4%）。VEGFR2的表达与临床分期（X2=21.414，P=0.045）和组织学类型（X2=26.911，P=0.008）相关。ES阳性表达140例（54.9%）。ES的表达与临床分期相关（X2=26.504，P=0.009）。评价VEGF/ES和VEGFR2/ES的预后参考价值，血管平衡组预后与血管生成抑制组相近。促血管生成组存活时间最短。
结论 术后肿瘤组织VEGF/ES和VEGFR2/ES数值对NSCLC术后患者有预后参考价值。肿瘤组织表达有促进血管生成因素的非小细胞肺癌患者术后预后较差。 |
| 英文摘要: |
| Objective: The aim of our study was to detect the expression of angiogenesis inhibitory proteins and
angiogenesis promotive proteins in the postoperative tumor tissue of non-small cell lung cancer (NSCLC)
patients. We also investigated the relationship of protein expression with clinical characteristics and
prognosis.
Methods: We examined the expression of vascular endothelial growth factor (VEGF), VEGF receptor 2
(VEGFR2), and endostatin (ES) proteins in 255 specimens resected from NSCLC patients, using immune
histochemistry (IHC). We then evaluated the relationships between the expression of the three proteins
and clinical characteristics such as stage, histological type, differentiation, gender, tobacco use, and
age. According to the value of VEGF/ES, we divided the cohort into angiogenesis-promoting group A,
angiogenesis-inhibiting group A, and balance group A. The survival differences in the three groups were
evaluated to determine the prognostic value of VEGF/ES. Similarly, we tested the prognostic value of
VEGFR2/ES.
Results: VEGF-positive expression was observed in 93 patients (36.4%). VEGF expression was not
correlated with the clinical characteristics. VEGFR2-positive expression was observed in 103 patients
(40.4%). The expression of VEGFR2 was correlated with the clinical stage (χ2 = 21.414, P = 0.045) and
histological type (χ2 = 26.911, P = 0.008). ES-positive expression was observed in 140 patients (54.9%).
The expression of ES was correlated with the clinical stage (χ2 = 26.504, P = 0.009). When evaluating
the prognostic values of VEGF/ES and VEGFR2/ES, the prognosis of the angiogenesis balance group
was similar to that of the angiogenesis-inhibiting group. The minimum survival time was observed in the
angiogenesis-promoting group.
Conclusion: VEGF/ES and VEGFR2/ES in resected tumors have prognostic value in postoperative
NSCLC patients. The survival time of the population with predominant angiogenic factors was short. |
|
View Full Text
Download reader HTML全文 |
| Close |
|
|
|